Intellia Therapeutics Inc... (NTLA)

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research...

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price ...

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by W...

Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value.

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...

News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling B...

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.